::ODMA	MHODMA\iManage;215591;1 OIPE PATENT APPLICATION 6
R!VW/T 04/19/01	AD/hbh(amg) DOCKET NO.: 2079.1042-001 ## 4/26/
	IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED
Applic	
Applic	ation No.: 09/663,320 Group Art Unit: 1614 TECH CENTER 1600/29
Filed:	September 15, 2000 Examiner: Not Assigned
Title:	KINASE INHIBITORS AS THERAPEUTIC AGENTS
	CERTIFICATE OF MAILING  I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231  on 04/19/01
	INFORMATION DISCLOSURE STATEMENT
	ant Commissioner for Patents ngton, D.C. 20231
Sir: This Ir	formation Disclosure Statement is submitted:
[ ]	under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)
[X]	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
[ ]	under 37 CFR 1.97(c) together with either:
	[ ] a Statement under 37 CFR 1.97(e), as checked below, or
	[ ] a \$180.00 fee under 37 CFR 1.17(p), or  (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
[]	under 37 CFR 1.97(d) together with:
	[ ] a Statement under 37 CFR 1.97(e), as checked below, and
	[ ] a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
[ ]	under 37 CFR 1.97(i): Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

## Statement Under 37 CFR 1.97(e)

[	]	any co	tem of information contained in this Information Disclosure Statement was first cited in mmunication from a foreign patent office in a counterpart foreign application not more tree months prior to the filing of this Information Disclosure Statement; or				
[	]	knowle in the i	m of information contained in this Information Disclosure Statement was cited in a unication from a foreign patent office in a counterpart foreign application, and, to the edge of the undersigned, after making reasonable inquiry, no item of information contained information disclosure statement was known to any individual designated in 37 CFR more than three months prior to the filing of this Information Disclosure Statement.				
<u>St</u>	atem	ent Unc	der 37 CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000				
[	]	commi was no	tem of information contained in the Information Disclosure Statement was cited in a unication from a foreign patent office in a counterpart application and this communication at received by any individual designated in § 1.56(c) more than thirty days prior to the of the Information Disclosure Statement.				
[ ]	X ]	Enclos	ed herewith is form PTO-1449:				
		[X]	Copies of the cited references are enclosed.				
		[ ]	Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]				
		[ X ]	The listed references were cited in the enclosed International Search Report in a counterpart foreign application. AM3 and AN3.				
		[X]	The listed reference was cited in the enclosed International Search Report in a commonly owned application. AO3.				
	X ]	The "concise explanation" requirement (non-English references) for reference AO3, AQ2, and AL3 under 37 CFR 1.98(a)(3) is satisfied by:					
		[]	the explanation provided on the attached sheet.				
		[ ]	the explanation provided in the Specification.				
		[ x ]	submission of the enclosed International Search Report.				
		[x]	the enclosed English language abstract.				

## [X] Applicant requests that the following pending applications be considered:

Examiner's Initials	
	U.S. Patent Application No. 09/399,083, by inventors David Calderwood, Lee Arnold, Hormoz Mazdiyasni, Gavin C. Hirst, Bojuan B. Deng, David N. Johnston, Paul Rafferty, Gerald B. Tometski, Helen L. Twigger and Rainer Munschauer, filed September 17, 1999, Docket No.: 2079.1020-002
	U.S. Patent Application No. 09/381,036,by inventors David J. Calderwood, David N. Johnston, Paul Rafferty, Helen L. Twigger, Rainer Munschauer and Lee D. Arnold, filed September 15, 1999, Docket No.: 2079.1020-005
	U.S. Patent Application No. 09/537,167,by inventors Gavin C. Hirst, David Calderwood, Rainer Munschauer, Lee D. Arnold, David N. Johnston and Paul Rafferty, filed March 29, 2000, Docket No.: 2079.1032-003
	U.S. Patent Application No. 09/663,780,by inventors Gavin C. Hirst, Paul Rafferty, Kurt Ritter, David Calderwood, Neil Wishart, Lee D. Arnold and Michael M. Friedman, filed September 15, 2000, Docket No.: 2079.1040-001
	U.S. Patent Application No. 09/815,310,by inventors Gavin C. Hirst, Paul Rafferty, Michael M. Friedman, Kurt Ritter and David Calderwood, filed March 22, 2001, Docket No.: 2079.1040-009
	U.S. Patent Application No. 60/278,047,by inventors Gavin C. Hirst, Paul Rafferty, Neil Wishart, Lee D. Arnold, Kurt Ritter, David Calderwood and Michael M. Friedman, filed March 22, 2001, Docket No.: 2079.1040-010
	Examiner Date
[X	A copy of each above-cited application, including the current claims, is enclosed.
[	A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

## Method of payment:

- [ ] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- [ ] Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.
- [X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Theresa A. Devlin

Registration No.: 45,361 Telephone: (781) 861-6240 Facsimile: (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated: 4/19/01

PTO-1449 REPRODUCED				ATTORNEY DOCKET NO. 2079.1042-001	APPLICATION NO. 09/663,320				
	INFOR	MATION DISCLOSURE CA IN AN APPLICATION	TAN E JOSE	APPLICANT Gavin C. Hirst, et al.	<u>_                                    </u>	•			
	(Use	April 18, 2001 several sheets if ne	APR 2 5 2001	FILING DATE September 15, 2000	GROUP 1614	, <u>.</u>			
			W	PATENT DOCUMENTS					
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING IF APPROPI	,	
	AA	4,140,851	02/20/79	Townsend	536	24			
	AB	4,229,453	10/21/80	Roth et al.	424	251			
	AC	4,892,865	01/09/90	Townsend et al.	514	43			
	AD	4,927,830	05/22/90	Pownsend et al.	514	258			
	AE	4,968,686	11/96/90	Townsend et al.	514	258			
	AF	4,996,206	02/26/91	Taylor et al.	514	258			
	AG	5,028,608	07/02/91	Taylor et al.	514	258			
	АН	5,248,775	09/28/93	Taylor et al.	544	280		_	
	AI	5,254,687	10/19/93	Taylor et al.	<b>7</b> 544	280			
	AJ	5,344,932	09/06/94	Taylor	544	280			
	AK	5,349,064	09/20/94	Akimoto et al.	544	280			
		,	FOREIG	N PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLA YES	NOITA ON	
	AL	WO 94/17803	18-AUG-94	PCT					
	AM	WO 96/10028	04-APR-96	PCT	•				
	AN	WO 96/31510	10-OCT-96	PCT					
	AO	WO 96/40686	19-DEC-96	PCT					
	AP	WO 96/40705	19-DEC-96	PCT					
	AQ	WO 96/40706	19-DEC-96	PCT					
	·	OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertinent	Pages,	Etc.)			
	AR	Hanke, J.H., et al., "Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor," J. Biol. Chem., 271 (2):695-701, (1996).							
	AS	Missbach, M., et al., "A Novel Inhibitor of the Tyrosine Kinase Src Suppresses Phosphorylation of Its Major Cellular Substrates and Reduces Bone Resorption In Vitro and in Rodent Models In Vivo," Bone, 24 (5): 437-449, (1999).							
		437-449, (1999).	<u> </u>		Traxler, P.M., et al., "4-(Phenylamino)pyrrolopyrimidines: Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase," J. Med. Chem., 39: 2285-2292, (1996).				
	РΤ	Traxler, P.M., & Selective, ATP S	et al., "4- Site Directe	ed Inhibitors of the EG	F-Recep			d	
EXAMIN		Traxler, P.M., & Selective, ATP S	et al., "4- Site Directe	ed Inhibitors of the EG	F-Recep			d	

9 REPRO	DDUCED		ATTORNEY DOCKET NO. 2079.1042-001	APPLICATION NO. 09/663,320			
INFOR	MATION DISCLOSURE CI	TATON E					
	1	APR 2 5 2001					
(Use	- 12	با ا	FILING DATE September 15, 2000	GROUP 1614			
		TRADEMARKS.	PATENT DOCUMENTS			<u> </u>	
	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	IF	
AA2	5,416,211	05/16/95	Barnett et al.	544	280		
AB2	5,593,997	01/14/97	Dow et al.	514	258		
AC2	5,594,121	01/14/97	Froehler et al.	536	23.5		
AD2	5,612,482	93/18/97	Barnett et al.	544	280		
AE2	5,639,757	96/17/97	Dow et al.	514	261		
AF2	5,644,057	07/01/97	Yuan et al.	544	280		
AG2	5,644,058	07/01/97	Barnett et al.	544	280		
AH2	5,665,721	09/09/97	Bhagwat et al.	514	253		
AI2	5,686,457	11/11/97	Traxler et al.	514	258		
AJ2	5,721,356	02/24/98	Ugarkar et al.	536	27.2		
AK2	5,726,302	03/10/98	Ugarkar et al.	536	27.13		
		FOREIG	n patent documents				
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLA YES	NO NO
AL2	WO 96/40707	19-DEC-96	PCT	/			
AM2	WO 97/02266	23-JAN-97	PCT				
AN2	WO 97/03069 .	30-JAN-97	PCT				
A02	WO 97/13771	17-APR-97	PCT	٠			
AP2	WO 97/28161	07-AUG-97	PCT		)		
AQ2	WO 97/32879	12-SEP-97	PCT				
	OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertinent	Pages,	Etc.)		
AU	Showalter, H.D.H., et al., "Synthesis and SAR for a series of 4-substituted 1H-pyrimido [4,5-b] and 5H-pyrimido [5,4-b]indoles as EGF receptor tyrosine kinase inhibitors," Proceedings of the American Association for Cancer Research, 37, March 1996, (abstract).						
AV	Dave, C.G., et al., "Synthesis & Biological Activity of Pyrrolo[2,3-d] pyrimidines," Indian J. Chem., 27B: 778-780, (1988).					d]	
IER			DATE CONSIDERED				
	(Use  (Use  AA2  AB2  AC2  AD2  AF2  AG2  AH2  AI2  AJ2  AV2  AV2  AV2  AV2  AV2  AV2  AV	INFORMATION DISCLOSURE CITN AN APPLICATION April 18, 2001 (Use several sheets if neck  DOCUMENT NUMBER  AA2 5,416,211 AB2 5,593,997 AC2 5,594,121 AD2 5,612,482 AE2 5,639,257 AF2 5,644,057 AG2 5,644,058 AH2 5,665,721 AI2 5,686,457 AJ2 5,721,356 AK2 5,726,302  DOCUMENT NUMBER  AL2 WO 96/40707 AM2 WO 97/03069 AO2 WO 97/13771 AP2 WO 97/03069 AO2 WO 97/13771 AP2 WO 97/28161 AQ2 WO 97/32879  OTHER DOCUMENTS  AU Showalter, H.D.F. substituted 1H-preceptor tyrosin Association for AV Dave, C.G., et apprimidines," In	INFORMATION DISCLOSURE CLTATFON IN AN APPLICATION APRIL 18, 2001  (Use several sheets if necksary)  APR 2 5 2001  (Use several sheets if necksary)  APR 2 5 2001  (Use several sheets if necksary)  APR 2 5 2001  (Use several sheets if necksary)  APR 2 5 2001  (Use several sheets if necksary)  APR 2 5 2001  (Use several sheets if necksary)  APR 2 5 2001  (Use several sheets if necksary)  APR 2 5 2001  (Use several sheets if necksary)  APR 2 5 2001  (Use several sheets if necksary)  APR 2 5 2001  (Use several sheets if necksary)  APR 2 5 2001  (Use several sheets if necksary)  APR 2 5 2001  (Use several sheets if necksary)  APR 2 5 2001  (Use several sheets if necksary)  APR 2 5 2001  (Including Autority)  APP WO 97/28161  APP WO 97/32879  APP OTHER DOCUMENTS (Including Autority)  APP OTHER DOCUMENTS (Including Autority)	NAME	NFORMATION DISCLOSURE CLATON IN AN APPLICATION (Use several sheets if neckspary)   September 15, 2000   1614	NAME	INFORMATION DISCLOSURE CYATRON  April 18, 2001  April 18, 2001

PTO-144	9 REPRO	DDUCED .		ATTORNEY DOCKET NO. 2079.1042-001	APPLICATION NO. 09/663,320			
	INFO	RMATION DISCLOSURE CO IN AN APPLICATION		APPLICANT Gavin C. Hirst, et al.				
	(Use	April 18, 2001 several sheets if nece	.sAPR 2 5 2001 (	FILING DATE September 15, 2000	GROUP 1614	, <del>-</del> ,	<u> </u>	
				PATENT DOCUMENTS				
EXAM- INER INI- TIAL		DOCUMENT NUMBER	TRADEMAN DATE	NAME	CLASS	SUB- CLASS	FILING IF APPROP	7
	AA3	5,763,596	06/09/98	Boyer et al.	536	27.13	<del></del>	
	AB3	5,763,597	06/09/98	Ugarkar et al.	536	27.13		
	AC3	5,834,469	11)/10/98	Elliott et al.	514	249		
					_			
		1						
			7					
,		· · · · · · · · · · · · · · · · · · ·					····	
				( )				
					<b>&gt;</b> .			
<del>                                     </del>	<u> </u>		<u> </u>			<u>k</u>		
	[		FOREIG	N PATENT DOCUMENTS				
		DOCUMENT NUMBER	FOREIG DATE	N PATENT DOCUMENTS  COUNTRY	CLASS	OB- CLASS	TRANSL. YES	NOITA
	AL3	DOCUMENT NUMBER WO 97/34895			CLASS	B S S S S S S S S S S S S S S S S S S S		
	AL3		DATE	COUNTRY	CLASS	OB CLASS		
		WO 97/34895	DATE 25-SEP-97	COUNTRY	CLASS	BB- CLASS		
	АМ3	WO 97/34895 WO 98/41525	DATE 25-SEP-97 24-SEP-98	COUNTRY PCT PCT	CLASS	BB-CIASS		
	AM3	WO 97/34895 WO 98/41525 WO 00/44728	DATE  25-SEP-97  24-SEP-98  03-AUG-00	PCT PCT	CLASS	BB- C1Asy		NO
	AM3 AN3 AO3	WO 97/34895 WO 98/41525 WO 00/44728 DE 30 36 390 A1	DATE  25-SEP-97  24-SEP-98  03-AUG-00  13-MAY-82	COUNTRY PCT PCT PCT GERMANY	CLASS	CLASS		NO
	AM3 AN3 AO3 AP3	WO 97/34895 WO 98/41525 WO 00/44728 DE 30 36 390 A1 EP 0 402 903 A1	DATE  25-SEP-97  24-SEP-98  03-AUG-00  13-MAY-82  19-DEC-90	PCT PCT PCT GERMANY EPO	CLASS	CLASS		NO
	AM3 AN3 AO3 AP3 AQ3	WO 97/34895 WO 98/41525 WO 00/44728 DE 30 36 390 A1 EP 0 402 903 A1 EP 0 496 617 A1 EP 0 795 556 A1	DATE  25-SEP-97  24-SEP-98  03-AUG-00  13-MAY-82  19-DEC-90  29-JUL-92  17-SEP-97	COUNTRY PCT PCT PCT GERMANY EPO EPO		CLASS		NO
	AM3 AN3 AO3 AP3 AQ3	WO 97/34895 WO 98/41525 WO 00/44728 DE 30 36 390 A1 EP 0 402 903 A1 EP 0 496 617 A1 EP 0 795 556 A1	DATE  25-SEP-97  24-SEP-98  03-AUG-00  13-MAY-82  19-DEC-90  29-JUL-92  17-SEP-97	COUNTRY PCT PCT PCT GERMANY EPO EPO		CLASS		NO
	AM3 AN3 AO3 AP3 AQ3	WO 97/34895 WO 98/41525 WO 00/44728 DE 30 36 390 A1 EP 0 402 903 A1 EP 0 496 617 A1 EP 0 795 556 A1	DATE  25-SEP-97  24-SEP-98  03-AUG-00  13-MAY-82  19-DEC-90  29-JUL-92  17-SEP-97	COUNTRY PCT PCT PCT GERMANY EPO EPO		CLASS		NO
	AM3 AN3 AO3 AP3 AQ3	WO 97/34895 WO 98/41525 WO 00/44728 DE 30 36 390 A1 EP 0 402 903 A1 EP 0 496 617 A1 EP 0 795 556 A1	DATE  25-SEP-97  24-SEP-98  03-AUG-00  13-MAY-82  19-DEC-90  29-JUL-92  17-SEP-97	COUNTRY PCT PCT PCT GERMANY EPO EPO		CLASS		NO
	AM3 AN3 AO3 AP3 AQ3	WO 97/34895 WO 98/41525 WO 00/44728 DE 30 36 390 A1 EP 0 402 903 A1 EP 0 496 617 A1 EP 0 795 556 A1	DATE  25-SEP-97  24-SEP-98  03-AUG-00  13-MAY-82  19-DEC-90  29-JUL-92  17-SEP-97	COUNTRY PCT PCT PCT GERMANY EPO EPO		CLASS		NO
EXAMIN	AM3 AN3 AO3 AP3 AQ3 AL4	WO 97/34895 WO 98/41525 WO 00/44728 DE 30 36 390 A1 EP 0 402 903 A1 EP 0 496 617 A1 EP 0 795 556 A1	DATE  25-SEP-97  24-SEP-98  03-AUG-00  13-MAY-82  19-DEC-90  29-JUL-92  17-SEP-97	COUNTRY PCT PCT PCT GERMANY EPO EPO		CLASS		ОИ